RegulatoryJul 20, 2026, 09:02 AM
Anavex Life Sciences Submits Nasdaq Compliance Plan
AI Summary
Anavex Life Sciences Corp. submitted a Compliance Plan to the Nasdaq Listing Qualifications Department on July 20, 2026. This plan addresses the company's non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the untimely filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The deficiency notification was received on May 20, 2026, but currently has no immediate effect on the company's stock listing. The Compliance Plan is under review by Nasdaq Staff, who may grant an extension if accepted.
Key Highlights
- Anavex Life Sciences submitted a Compliance Plan to Nasdaq on July 20, 2026.
- Plan aims to regain compliance with Nasdaq Listing Rule 5250(c)(1).
- Non-compliance due to untimely filing of Quarterly Report on Form 10-Q for March 31, 2026.
- Deficiency notification received from Nasdaq on May 20, 2026.
- No immediate effect on the company's common stock listing on Nasdaq Global Select Market.
- Nasdaq Staff is reviewing the plan; acceptance may grant an extension for compliance.
Price Impact
More from AVXL